Daniel Carlat
Blogger and Publisher at Freelance
Founded and Published by Daniel Carlat, MD. Unbiased since 2003. Subscribe: https://t.co/makW8HKzi2 #psychtwitter
Articles
-
4 days ago |
thecarlatreport.com | Daniel Carlat
GLP-1 agonists may get the spotlight—but they’re not the only option. Many patients can’t afford them, don’t want the side effects, or prefer to stick with psychiatric meds they already know. In the May issue of The Carlat Psychiatry Report, Dr. Chris Aiken reviews psychotropics that can lead to weight loss. For seasoned clinicians, some may be familiar—but the value here is having them all in one place, with clinical nuance.
-
4 days ago |
thecarlatreport.com | Daniel Carlat
When patients are acutely psychotic, manic, or suicidal, our impulse is to fine tune the meds. But a few years ago—while working primarily inpatient—I realized I was leaning too heavily on medication. My patients needed more. Then I came across a powerful framework by Michelle Stein and Michelle Jacobo that reframed how I think about inpatient therapy.
-
1 week ago |
thecarlatreport.com | Daniel Carlat
TD affects ~2.6 million people in the U.S., but only 40,000 are being treated We now have effective meds—valbenazine was approved in 2017—but the bigger challenge is detection Clinicians are told to use the AIMS at every visit, yet many don’t feel confident using it (or don’t use it at all) This new video-based tool uses AI to flag TD from short patient clips—even outside the clinic It caught TD with 82% sensitivity and 82% specificity, outperforming trained human raters It works across age,...
-
1 week ago |
thecarlatreport.com | Daniel Carlat
I just read a Lilly-sponsored CME on Medscape featuring Dr. Malaz Boustani—a respected geriatrician doing critical work with underserved communities. But this isn't just education—it's marketing for Lilly’s anti-amyloid drug Donabemab. Link: https://lnkd.in/evwta6p8Here’s what Lilly is really doing:Amplifying the Problem:“99% miss early MCI diagnosis.”This frames clinicians as falling short—and primes them for the solution Lilly will offer.
-
2 weeks ago |
thecarlatreport.com | Daniel Carlat
At Carlat Publishing, we regularly debate trends in psychiatry—and neurodivergence is one of today’s most charged topics. Let’s call it opinion divergence: Some on our team feel that the DSM-5 term “autism spectrum disorder” is politically insensitive. Others see it as clinically essential. That conversation got me thinking: How did we get to a place where a diagnosis is considered offensive?
Try JournoFinder For Free
Search and contact over 1M+ journalist profiles, browse 100M+ articles, and unlock powerful PR tools.
Start Your 7-Day Free Trial →X (formerly Twitter)
- Followers
- 7K
- Tweets
- 3K
- DMs Open
- No
RT @chrisaikenmd: Lurasidone for anxiety in bipolar depression? This analysis suggests it helps, more in 20-60 mg range than 80-120 mg.…
Did you purchase the Medication Fact Book for Psychiatric Practice from Carlat Publishing already? Good news! You can use the app version of this book! Here's how. https://t.co/SE4E21yl35 #Psychopharmacology #pharmacology #psychiatry https://t.co/Fx1DDI4F7B
𝐂𝐡𝐨𝐨𝐬𝐢𝐧𝐠 𝐀𝐃𝐇𝐃 𝐌𝐞𝐝𝐬: 𝐀 𝟑 𝐌𝐢𝐧𝐮𝐭𝐞 𝐎𝐯𝐞𝐫𝐯𝐢𝐞𝐰 ADHD pharmacology can feel overwhelming. Dozens of formulations. Full Post from Dr. Carlat: https://t.co/SkNZzBr21H... #adhd #adhdtreatment #Vyvanse #stimulants #psychiatry #psychophamacology https://t.co/BLPxgf6x8W